Journal
TRANSPLANTATION PROCEEDINGS
Volume 42, Issue 9, Pages 3798-3802Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.transproceed.2010.06.031
Keywords
-
Categories
Funding
- Huadong Pharmaceutical Co, Hangzhou, China
- National Nature Science Foundation of China [30772056, U0832009]
Ask authors/readers for more resources
The effect of astilbin on acute graft rejection was investigated in C57BL/6 mice carrying BALB/c hearts heterotopically transplanted into the neck vessels. Daily treatment with astilbin (50, 125, or 250 mg/kg intraperitoneally) significantly prolonged the survival of grafts in a dose-dependent manner, when cyclosporine (CsA; 5 mg/kg) was co-administered with astilbin (250 mg/kg), there was more potent immunosuppression than that solely achieved by 20 mg/kg CsA. Addition of 10 mg/mL astilbin significantly inhibited the proliferation and activation of T cells, as determined by H-3 thymidine deoxyribose uptake, Western blots for nuclear factor kappa B and p38, and 1-way mixed lymphocyte reactions (MLR). Mature and antigen-presenting functions of dendritic cells (DCs) also were inhibited by astilbin (10 mg/mL), as determined by morphologic observations, flow cytometry, and MLR. These observations suggested that astilbin is a potential candidate for immunosuppressive therapy after heart engraftment. Inhibiting the maturation and antigen-presenting function of DCs and thus preventing T-cells activation is a possible mechanism underlying its inhibitory effects on acute heart allograft rejection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available